STAT
OCTOBER 23, 2023
The risks of severe neonatal morbidity, neonatal death, and admission to the neonatal intensive care unit were all significantly lower during the first month of birth in infants whose mothers were vaccinated against Covid-19, and protection against the virus continued for up to six months after birth, according to a new study published Monday in JAMA Pediatrics.
ALiEM - Pharm Pearls
OCTOBER 23, 2023
A 32-year-old man with a history of traumatic globe rupture from a stab wound two months ago, status post repair, presented to the emergency department for worsening right eye pain and green malodorous drainage for the past three days. These symptoms started when he got a fleck of sawdust in the right eye about four days prior to presentation, which he was able to brush out with his finger.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 23, 2023
Fixing the U.S. health care system can seem like a herculean task. But the solution is “actually very simple,” according to Massachusetts Institute of Technology economist Amy Finkelstein. In their recent book “ We’ve Got You Covered: Rebooting American Health Care ,” Finkelstein and Stanford economist Liran Einav describe how years of research have led them to the conclusion that the best way forward is for the U.S. to offer universal basic health care coverag
PharmaVoice
OCTOBER 23, 2023
Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
OCTOBER 23, 2023
When her life was upturned by an accumulating array of confounding health problems, Meghan O’Rourke turned, like so many writers before her, to metaphor. Her body wracked with fatigue was a mound of sand. Her descent into illness was Hemingway’s description of going broke: gradually, then suddenly. The chronically ill patient dejected after fruitless interactions with doctors was nearly invisible, and solitary.
BioPharma Dive
OCTOBER 23, 2023
The trial, which is ongoing in the U.K. and New Zealand, has been on hold in the U.S. since late last year as the FDA sought more details on Verve’s in vivo treatment for heart disease.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
The Pharmacist
OCTOBER 23, 2023
A UK-wide advisory board has been set up to bring together pharmacy professionals amid imminent changes to the professional landscape. Over the next three to five years, the Independent Pharmacy Professional Leadership Advisory Board aims to support and enable collaborative working between organisations representing pharmacists and pharmacy technicians in different settings.
STAT
OCTOBER 23, 2023
In the last two decades, Black Americans have suffered 1.63 million excess deaths compared to white Americans. Experts gathered at the STAT Summit in Boston last week to discuss the crisis of Black deaths in the U.S. and interventions that can help advance health equity. “If we continue to have a maternal health crisis, if we continue to have an infant mortality crisis … then we’re going to potentially see a situation or circumstance where Black people can be extinct in the
Pharma Times
OCTOBER 23, 2023
On 10 to 11 October 2023, the seventh FlyPharma Conference Europe successfully concluded in Vienna, Austria - News - PharmaTimes
STAT
OCTOBER 23, 2023
Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease. The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
OCTOBER 23, 2023
STARMAP will accelerate the selection of AZ’s best molecule candidates - News - PharmaTimes
STAT
OCTOBER 23, 2023
Almost as soon as ChatGPT was released to the public, doctors began focusing on how they could harness artificial intelligence to improve patient care. Yet even as AI is providing doctors with increasingly sophisticated data, the information available to patients has stagnated. The stark reality is that there’s far more information available today to guide you in betting a few dollars on the performance of your local sports team than in betting your life on the performance of your local h
Pharma Times
OCTOBER 23, 2023
STARMAP will accelerate the selection of AZ’s best molecule candidates - News - PharmaTimes
STAT
OCTOBER 23, 2023
Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off. As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT.
BioPharma Dive
OCTOBER 23, 2023
The clearance of the pentavalent shot Penbraya adds to Pfizer’s infectious disease portfolio as it adjusts to slumping COVID-19 vaccine sales.
STAT
OCTOBER 23, 2023
MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months. On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the d
World Pharma News
OCTOBER 23, 2023
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.
STAT
OCTOBER 23, 2023
MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well. The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells.
Drug Patent Watch
OCTOBER 23, 2023
Annual Drug Patent Expirations for FINACEA Finacea is a drug marketed by Leo Pharma As and is included in two NDAs. It is available from three suppliers. There are eight… The post New patent expiration for Leo Pharma drug FINACEA appeared first on DrugPatentWatch - Make Better Decisions.
STAT
OCTOBER 23, 2023
Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down? Gline created $5 billion from $50 million — in less than one year. Regular readers know that every December, I choose a best biopharma CEO.
BioPharma Dive
OCTOBER 23, 2023
A combination of Seagen and Astellas’ antibody-drug conjugate Padcev with Merck’s Keytruda dramatically improved survival in first-line bladder cancer.
STAT
OCTOBER 23, 2023
MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo. At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations.
European Pharmaceutical Review
OCTOBER 23, 2023
An intravesical drug delivery system designed to provide sustained local release of gemcitabine into the bladder, has enabled 77 percent of bladder cancer patients (23 out of 30) to achieve a complete response (CR) in the Cohort 2 of the Phase IIb SunRISe-1 study. TAR-200 is indicated for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) CIS (carcinoma in situ)-positive in individuals who are ineligible for, or decline radical cystectomy.
STAT
OCTOBER 23, 2023
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because — you know what we will say — the predictable routine of online meetings and deadlines has returned. But what can you do? The world, such as it is, somehow continues to spin. So to cope, we are quaffing cups of stimulation.
BioPharma Dive
OCTOBER 23, 2023
Effective marketing measurement requires objectivity, connected data, transparency, a track record of innovation and a proven ability to execute.
STAT
OCTOBER 23, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see data from ESMO showing that Roche’s alectinib works well in some early stage lung cancers, see our first preventative dengue pill, and more.
European Pharmaceutical Review
OCTOBER 23, 2023
In tablet compression, there are a range of factors which contribute to a successful production run. 1 In pharmaceutical manufacturing, the high level of final product quality is the major driver. Tablets should be defect-free and compliant to good manufacturing practice (GMP) aspects and final-user requirements. The most common defects in tableting are classified as visual or functional 2 : visual issues compromise tablet quality without affecting its functionality, something which functional i
PharmExec
OCTOBER 23, 2023
Penbraya indicated as the first and only vaccine for the prevention of the five most common serogroups in adolescents.
European Pharmaceutical Review
OCTOBER 23, 2023
As part of an acquisition agreement of over $7 billion, Roche will gain rights to a novel TL1A directed antibody for inflammatory bowel disease (IBD). Roche has agreed to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc for $7.1 billion. Roche will also pay a near-term milestone payment of $150 million.
pharmaphorum
OCTOBER 23, 2023
Embracing generative AI will enhance, not replace, the humanity in commercial models Mike.
Pharmaceutical Technology
OCTOBER 23, 2023
At ESMO 2023, interim results from the Phase III LITESPARK-005 trial evaluating MSD’s Welireg (belzutifan) as a treatment for patients with previously treated advanced clear cell renal cell carcinoma (RCC) were presented.
pharmaphorum
OCTOBER 23, 2023
Understanding the complex rare disease and specialty pharmaceutical landscape Mike.
Pharmafile
OCTOBER 23, 2023
AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who need systemic therapy following platinum-based chemotherapy with or without immunotherapy.
pharmaphorum
OCTOBER 23, 2023
ESMO: Trials end 20-year hiatus in cervical cancer therapy Phil.
Pharmafile
OCTOBER 23, 2023
Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by Roivant Sciences and Pfizer. This agreement includes development, manufacturing and commercialisation rights in the US and Japan for the company’s RVT-3101, a TL1A directed antibody for the treatment of inflammatory bowel disease.
Expert insights. Personalized for you.
363 
Let's personalize your content